Perhaps continuation of targeted albumin infusions beyond 2 weeks, which had been shown to have beneficial effects in the ANSWER trial (52), could be further investigated in patients with decompensated cirrhosis, especially those with higher organ system disconnection (see graphical abstract). This evidence concerns the gene ALB and Cirrhosis.